Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Relapsed/Refractory Urothelial Carcinoma
NCT02109328Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Aug 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in urothelial carcinoma (UC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Aug 2014; status: completed.
02
Drugs
alisertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02109328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109328.